Literature DB >> 26578639

Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile.

I Barchetta1, C Alessandri1, L Bertoccini1, F A Cimini1, L Taverniti1, M Di Franco1, A Fraioli1, M G Baroni1, M G Cavallo2.   

Abstract

OBJECTIVE: Osteopontin (OPN) is a sialoprotein implicated in different immunity and metabolic pathways. Capable of activating dendritic cells and inducing Th1-Th17-mediated tissue damage, OPN plays a significant role in the development/progression of several autoimmune diseases; interestingly, it was also shown that OPN participates in the acute pancreatic islets response to experimentally induced diabetes in non-obese diabetic (NOD) mice. Furthermore, OPN promotes adipose tissue dysfunction, systemic inflammation and insulin resistance. Our aims of this study were to evaluate circulating OPN levels in adult patients with type 1 diabetes mellitus (T1DM) compared to non-diabetic control participants and to unravel clinical and biochemical correlates of OPN concentration.
DESIGN: Case-control study.
METHODS: We enrolled 54 consecutive T1DM patients referred to our diabetes outpatient clinic at Sapienza University of Rome and 52 healthy sex and age-comparable controls. The study population underwent clinical evaluation, blood sampling for biochemistry and complete screening for diabetes complications. Serum OPN levels were measured by MILLIPLEX Multiplex Assays Luminex.
RESULTS: T1DM patients had significantly higher serum OPN levels than controls (17.2±12.9 vs 10.5±11.6 mg/ml, P=0.009). OPN levels correlated with T1DM, higher blood pressure, BMI, creatinine, γ-GT, ALP and lower HDL; the association between high OPN levels and T1DM was independent from all confounders. No correlation was shown between OPN and HbA1c, C-peptide, insulin requirement, co-medications and diabetes duration.
CONCLUSIONS: This study demonstrates for the first time in a case-control study that adults with T1DM have increased serum OPN levels, and that higher OPN concentrations are associated with an unfavorable metabolic profile in these patients.
© 2016 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26578639     DOI: 10.1530/EJE-15-0791

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  14 in total

1.  High serum osteopontin levels are associated with prevalent fractures and worse lipid profile in post-menopausal women with type 2 diabetes.

Authors:  T Filardi; V Carnevale; R Massoud; C Russo; L Nieddu; F Tavaglione; I Turinese; A Lenzi; E Romagnoli; S Morano
Journal:  J Endocrinol Invest       Date:  2018-06-18       Impact factor: 4.256

2.  Osteopontin in Vascular Disease.

Authors:  Zoe Shin Yee Lok; Alicia N Lyle
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

Review 3.  Osteopontin in autoimmune disorders: current knowledge and future perspective.

Authors:  Canhua Xu; Yaohong Wu; Ning Liu
Journal:  Inflammopharmacology       Date:  2022-03-02       Impact factor: 5.093

4.  Expression-based Genome-wide Association Study Links OPN and IL1-RA With Newly Diagnosed Type 1 Diabetes in Children.

Authors:  Xiaofan Jia; Kyoko Toda; Ling He; Dongmei Miao; Satoru Yamada; Liping Yu; Keiichi Kodama
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

5.  Determinant of Osteopontin Levels in Microvascular Complications in Patients with Diabetes.

Authors:  Shaik Sarfaraz Nawaz; Khalid Siddiqui; Muhammad Mujammami; Obeed Alotaibi; Saud Sulaiman Alanazi; Mohamed Rafiullah
Journal:  Int J Gen Med       Date:  2022-04-27

6.  The Role of Osteopontin in the Pathogenesis and Complications of Type 1 Diabetes Mellitus in Children.

Authors:  Mohamed A Talat; Laila Metwaly Sherief; Hosam Fathy El-Saadany; Anwar Ahmed Rass; Rabab M Saleh; Maha Mahmoud Hamed Sakr
Journal:  J Clin Res Pediatr Endocrinol       Date:  2016-06-29

Review 7.  Weight Management in Patients with Type 1 Diabetes and Obesity.

Authors:  Adham Mottalib; Megan Kasetty; Jessica Y Mar; Taha Elseaidy; Sahar Ashrafzadeh; Osama Hamdy
Journal:  Curr Diab Rep       Date:  2017-08-23       Impact factor: 4.810

8.  Osteopontin Affects Insulin Vesicle Localization and Ca2+ Homeostasis in Pancreatic Beta Cells from Female Mice.

Authors:  Anna Wendt; Inês G Mollet; Anki Knutsson; Victor S Bolmgren; Anna Hultgårdh-Nilsson; Maria F Gomez; Lena Eliasson
Journal:  PLoS One       Date:  2017-01-20       Impact factor: 3.240

Review 9.  Osteopontin Bridging Innate and Adaptive Immunity in Autoimmune Diseases.

Authors:  Nausicaa Clemente; Davide Raineri; Giuseppe Cappellano; Elena Boggio; Francesco Favero; Maria Felicia Soluri; Chiara Dianzani; Cristoforo Comi; Umberto Dianzani; Annalisa Chiocchetti
Journal:  J Immunol Res       Date:  2016-12-20       Impact factor: 4.818

10.  The potential role of the osteopontin-osteocalcin-osteoprotegerin triad in the pathogenesis of prediabetes in humans.

Authors:  Giuseppe Daniele; Deidre Winnier; Andrea Mari; Jan Bruder; Marcel Fourcaudot; Zuo Pengou; Andrea Hansis-Diarte; Christopher Jenkinson; Devjit Tripathy; Franco Folli
Journal:  Acta Diabetol       Date:  2017-11-18       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.